+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiovascular Drugs - Market Analysis, Trends, and Forecasts

  • ID: 1227742
  • Report
  • 265 Pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca Plc
  • Eli Lilly and Company
  • Gilead Sciences
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical
  • MORE
Cardiovascular Drugs market worldwide is projected to grow by US$7.8 Billion, driven by a compounded growth of 1.4%. Renin-Angiotensin System Blockers, one of the segments analyzed and sized in this study, displays the potential to grow at over 1.1%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$7.6 Billion by the year 2025, Renin-Angiotensin System Blockers will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 1.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$344.2 Million to the region's size and clout in the next 5 to 6 years. Over US$242.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Renin-Angiotensin System Blockers will reach a market size of US$174.8 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 1.9% over the next couple of years and add approximately US$1.9 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • Abbott Laboratories, Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi-aventis U.S. LLC
  • Takeda Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Astrazeneca Plc
  • Eli Lilly and Company
  • Gilead Sciences
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical
  • MORE

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

Cardiovascular Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Cardiovascular Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 2: Cardiovascular Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017

TABLE 3: Cardiovascular Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: Renin-Angiotensin System Blockers (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 5: Renin-Angiotensin System Blockers (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 6: Renin-Angiotensin System Blockers (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Beta Blockers (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025

TABLE 8: Beta Blockers (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017

TABLE 9: Beta Blockers (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: Diuretics (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025

TABLE 11: Diuretics (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017

TABLE 12: Diuretics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 13: Anti-Clotting Agents (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025

TABLE 14: Anti-Clotting Agents (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017

TABLE 15: Anti-Clotting Agents (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025

TABLE 16: Antihyperlipidemics (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 17: Antihyperlipidemics (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 18: Antihyperlipidemics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 19: Other Drug Classes (Drug Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025

TABLE 20: Other Drug Classes (Drug Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017

TABLE 21: Other Drug Classes (Drug Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025

TABLE 22: Hypertension (Indication) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025

TABLE 23: Hypertension (Indication) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017

TABLE 24: Hypertension (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

TABLE 25: Hyperlipidemia (Indication) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 26: Hyperlipidemia (Indication) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 27: Hyperlipidemia (Indication) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 28: Coronary Artery Disease & Peripheral Artery Disease (Indication) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025

TABLE 29: Coronary Artery Disease & Peripheral Artery Disease (Indication) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017

TABLE 30: Coronary Artery Disease & Peripheral Artery Disease (Indication) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 31: Other Indications (Indication) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025

TABLE 32: Other Indications (Indication) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017

TABLE 33: Other Indications (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Cardiovascular Drugs Market Share (in %) by Company: 2019 & 2025

TABLE 34: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 35: Cardiovascular Drugs Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 36: United States Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 37: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025

TABLE 38: Cardiovascular Drugs Market in the United States by Indication: A Historic Review in US$ Million for 2009-2017

TABLE 39: United States Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

CANADA

TABLE 40: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 41: Canadian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 42: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

TABLE 43: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025

TABLE 44: Canadian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017

TABLE 45: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025

JAPAN

TABLE 46: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 47: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 48: Japanese Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 49: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025

TABLE 50: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017

TABLE 51: Japanese Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

CHINA

TABLE 52: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 53: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017

TABLE 54: Chinese Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

TABLE 55: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025

TABLE 56: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Indication: 2009-2017

TABLE 57: Chinese Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Cardiovascular Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 58: European Cardiovascular Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025

TABLE 59: Cardiovascular Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017

TABLE 60: European Cardiovascular Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 61: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 62: Cardiovascular Drugs Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 63: European Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 64: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025

TABLE 65: Cardiovascular Drugs Market in Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017

TABLE 66: European Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

FRANCE

TABLE 67: Cardiovascular Drugs Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 68: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 69: French Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 70: Cardiovascular Drugs Market in France by Indication: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 71: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017

TABLE 72: French Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

GERMANY

TABLE 73: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 74: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 75: German Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 76: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 77: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 78: German Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

ITALY

TABLE 79: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 80: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017

TABLE 81: Italian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

TABLE 82: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025

TABLE 83: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Indication: 2009-2017

TABLE 84: Italian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 85: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 86: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 87: United Kingdom Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 88: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025

TABLE 89: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017

TABLE 90: United Kingdom Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

SPAIN

TABLE 91: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 92: Spanish Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 93: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

TABLE 94: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025

TABLE 95: Spanish Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017

TABLE 96: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025

RUSSIA

TABLE 97: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 98: Cardiovascular Drugs Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 99: Russian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 100: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025

TABLE 101: Cardiovascular Drugs Market in Russia by Indication: A Historic Review in US$ Million for 2009-2017

TABLE 102: Russian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 103: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 104: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 105: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 106: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025

TABLE 107: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017

TABLE 108: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 109: Asia-Pacific Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 110: Cardiovascular Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017

TABLE 111: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 112: Cardiovascular Drugs Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 113: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 114: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 115: Cardiovascular Drugs Market in Asia-Pacific by Indication: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 116: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017

TABLE 117: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 118: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 119: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 120: Australian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 121: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 122: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 123: Australian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

INDIA

TABLE 124: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 125: Indian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 126: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

TABLE 127: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025

TABLE 128: Indian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017

TABLE 129: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025

SOUTH KOREA

TABLE 130: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 131: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 132: Cardiovascular Drugs Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025

TABLE 133: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 134: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 135: Cardiovascular Drugs Market Share Distribution in South Korea by Indication: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 136: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 137: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 138: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 139: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025

TABLE 140: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017

TABLE 141: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 142: Latin American Cardiovascular Drugs Market Trends by Region/Country in US$ Million: 2018-2025

TABLE 143: Cardiovascular Drugs Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 144: Latin American Cardiovascular Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 145: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 146: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017

TABLE 147: Latin American Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

TABLE 148: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025

TABLE 149: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Indication: 2009-2017

TABLE 150: Latin American Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 151: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 152: Cardiovascular Drugs Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 153: Argentinean Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 154: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025

TABLE 155: Cardiovascular Drugs Market in Argentina in US$ Million by Indication: A Historic Review for the Period 2009-2017

TABLE 156: Argentinean Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

BRAZIL

TABLE 157: Cardiovascular Drugs Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 158: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 159: Brazilian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 160: Cardiovascular Drugs Market in Brazil by Indication: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 161: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017

TABLE 162: Brazilian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

MEXICO

TABLE 163: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 164: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 165: Mexican Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 166: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 167: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 168: Mexican Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 169: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 170: Cardiovascular Drugs Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 171: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 172: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025

TABLE 173: Cardiovascular Drugs Market in Rest of Latin America by Indication: A Historic Review in US$ Million for 2009-2017

TABLE 174: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 175: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 176: Cardiovascular Drugs Market in the Middle East by Region/Country in US$ Million: 2009-2017

TABLE 177: The Middle East Cardiovascular Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 178: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 179: The Middle East Cardiovascular Drugs Historic Market by Drug Class in US$ Million: 2009-2017

TABLE 180: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

TABLE 181: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025

TABLE 182: The Middle East Cardiovascular Drugs Historic Market by Indication in US$ Million: 2009-2017

TABLE 183: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025

IRAN

TABLE 184: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 185: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 186: Iranian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

TABLE 187: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025

TABLE 188: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017

TABLE 189: Iranian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025

ISRAEL

TABLE 190: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 191: Cardiovascular Drugs Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 192: Israeli Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 193: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025

TABLE 194: Cardiovascular Drugs Market in Israel in US$ Million by Indication: A Historic Review for the Period 2009-2017

TABLE 195: Israeli Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 196: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 197: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017

TABLE 198: Saudi Arabian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

TABLE 199: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025

TABLE 200: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Indication: 2009-2017

TABLE 201: Saudi Arabian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 202: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 203: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 204: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025

TABLE 205: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 206: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 207: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Indication: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 208: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 209: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 210: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 211: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025

TABLE 212: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017

TABLE 213: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

AFRICA

TABLE 214: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 215: Cardiovascular Drugs Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 216: African Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

TABLE 217: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025

TABLE 218: Cardiovascular Drugs Market in Africa by Indication: A Historic Review in US$ Million for 2009-2017

TABLE 219: African Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBOTT LABORATORIES

ASTELLAS PHARMA US

ASTRAZENECA PLC

BAYER AG

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

BRISTOL-MYERS SQUIBB COMPANY

ELI LILLY AND COMPANY

F. HOFFMANN-LA ROCHE AG

GILEAD SCIENCES

JOHNSON & JOHNSON

MERCK & CO., INC.

NOVARTIS INTERNATIONAL AG

OTSUKA PHARMACEUTICAL

PFIZER

SANOFI-AVENTIS US

TAKEDA PHARMACEUTICAL COMPANY LIMITED

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories
  • Astellas Pharma Us
  • Astrazeneca Plc
  • Bayer Ag
  • Boehringer Ingelheim International GMBH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ag
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International Ag
  • Otsuka Pharmaceutical
  • Pfizer
  • Sanofi-Aventis Us
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll